Hormone-refractory prostate cancer
RecruitingStudy on Radiotherapy and Antiandrogens for Patients with Advanced Prostate Cancer Using Abiraterone Acetate and Enzalutamide
Study on Radiotherapy and Antiandrogens for Patients with Advanced Prostate Cancer Using Abiraterone Acetate and Enzalutamide
- Disease:Hormone-refractory prostate cancer
- Substances:Abiraterone AcetateEnzalutamide
Spain- Participants:18–64 years · 65+ years
- Substances:Abiraterone Acetate
- Sponsor:Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)












